Vinge advises Active Biotech in relation to directed new share issue
April 04, 2013
In March this year, Active Biotech AB (publ) conducted a directed new share issue to Investor AB (publ) pursuant to which Active Biotech procured SEK 270 million.
Vinge’s team consisted of partner Erik Sjöman and associate Christian Lindhé.
Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
Vinge has advised Studentbostäder i Norden AB (publ) in connection with its issuance of senior unsecured bonds in an amount of SEK 500 million (within a framework of SEK 750 million) and in parallel with the company's voluntary early redemption of previously issued bonds.